Abliva AB

Abliva AB is a biotechnology company based in Lund, Sweden, focused on the research and development of mitochondrial medicine. The company is advancing several pharmaceutical candidates, including KL1333, which is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases, and NV354, which is being prepared for clinical trials targeting Complex I deficiency in these diseases. Additionally, Abliva is developing NeuroSTAT for the treatment of traumatic brain injury, currently entering a Phase II/III adaptive clinical study. The company also has a CicloMulsion® pharmaceutical for reperfusion injury, which is undergoing a Phase III clinical study involving 1,000 patients. Abliva collaborates with various institutions and organizations, including Isomerase, Yungjin Pharm, and the University of Pennsylvania, to enhance its research and development efforts. Founded in 2000, Abliva was previously known as NeuroVive Pharmaceutical AB before rebranding in May 2020.